The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...

Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.

MELBOURNE, Australia and SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ...